Results of a phase III trial of rituximab biosimilar for first line treatment of aggressive follicular lymphoma.
Home / Resource Library / Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results